Paul LePage: PRESCRIPTION DRUGS
LePage Wanted to Restart Canadian Prescription Drug Program. In 2012 Kennebec Journal reported, “LePage wants to find a way to allow a Canadian company that sells mail-order prescription drugs at deep discounts to resume operations in Maine, his spokeswoman said… The Maine State Employees Association said Tuesday it looks forward to working with LePage and other elected officials so the company can resume deliveries in Maine. Sen. Troy Jackson, D-Allagash, plans to propose legislation to make it possible for CanaRx to do business here again.” [Kennebec Journal, 9/12/12]
In 2013, LePage Refused to Sign Bipartisan Legislation Allowing Mainers To Order Prescription Drugs From Certain Licensed Overseas Pharmacies Through The Mail. In June 2013, LePage allowed LD171 to become law without his signature. LD 171 as amended “amends the Maine Pharmacy Act to exempt from the licensure requirements of the Act licensed retail pharmacies that are located in Canada, the United Kingdom of Great Britain and Northern Ireland, the Commonwealth of Australia or New Zealand that meet the respective foreign country's statutory and regulatory requirements, as well as entities that contract to provide or facilitate the exportation of prescription drugs from these licensed retail pharmacies, and authorizes these retail pharmacies and entities to provide prescription drugs by mail or carrier to a resident of this State for that resident's personal use. It also amends the Maine Pharmacy Act to provide that nothing in the Act may be construed to prohibit individuals from ordering or receiving prescription drugs for their personal use from licensed retail pharmacies in the above-mentioned countries or contracting entities or to prohibit such a licensed retail pharmacy or contracting entity from dispensing, providing or facilitating the provision of prescription drugs from outside the United States.” The House accepted the “ought to pass as amended” report by a 107-37 vote. The Senate accepted the “ought to pass as amended” report by a 29-5 vote on 6/11/13 and the bill became law without the governor’s signature on 6/27/13. [State of Maine Legislature, LD 171, Roll Call #305, 6/13/13; State of Maine Legislature, Actions for LD 171, 6/27/13; Joint Standing Committee on Labor, Commerce, Research and Economic Development, Summaries of Bills, LD 171, July 2013]
- HEADLINE: “Maine To Allow Prescription-Drug Imports.” [Wall Street Journal, 10/11/13]
- HEADLINE: “New Maine Law Allows Importation Of Foreign Mail Order Prescription Drugs.” [Sun Journal, 6/28/13]
- Bangor Daily News: “First-In-The-Nation” Law Allowed For Residents To Purchase Prescription Drugs By Mail From Other Countries. “A federal judge has overturned Maine’s first-in-the-nation law allowing residents to purchase medication by mail from other countries. U.S. Chief District Judge Nancy Torresen’s ruling Monday comes more than a year after several Maine pharmacy groups filed suit against the state over the 2013 law, arguing it jeopardizes the safety of the nation’s prescription drug supply and opens the door to counterfeit and tainted medications.” [Bangor Daily News, 2/24/15]
- Bangor Daily News: With The Law’s Passage, Maine “Became The First In The Nation To Formally Defy Federal Regulations Prohibiting U.S. Residents From Importing Drugs Through Foreign Pharmacies, Which Often Sell The Same Medications For Half The Cost.” “When Maine passed its law in June 2013, the state became the first in the nation to formally defy federal regulations prohibiting U.S. residents from importing drugs through foreign pharmacies, which often sell the same medications for half the cost.” [Bangor Daily News, 2/24/15]
- The Law Allowed Maine Residents To Purchase Prescription Drugs Online From Pharmacies In Canada, The United Kingdom, Australia, And New Zealand. “The law allowed Maine residents to buy prescription drugs from Internet pharmacies in Canada, the U.K., Australia and New Zealand, which the U.S. government deems to have equivalent or greater drug safety and licensing regulations. Those countries, among others, can sell prescription drugs more cheaply because their governments cap prices or negotiate prices with drug makers.” [Bangor Daily News, 2/24/15]
- Bangor Daily News Editorial: “Showing Rare Bipartisan Agreement On An Approach To Making Health Care More Affordable,” The Legislature Passed A Bill That Lifted The Ban On Using International Firms For Mail Order Prescription Drugs. “With much less fanfare, legislators in recent days have taken positive actions to protect and enhance public health in Maine. Here are four examples: […] Showing rare bipartisan agreement on an approach to making health care more affordable, the Senate on Friday gave final passage to LD 171, a bill that lifts the August 2012 prohibition imposed by former Attorney General William Schneider on the use of international firms to fill mail order prescriptions.” [Editorial, Bangor Daily News, 6/16/13]
- Bangor Daily News Editorial: “The Bill Restores A Lower-Cost Medication Option” For State Workers, Portland City Workers, And The Employees Of Hardwood Products Co. “The bill restores a lower-cost medication option that for as far back as eight years ago proved beneficial to state workers, Portland city staff and employees of Hardwood Products Co., a private business in Guilford. Before Schneider intervened, employees and employers -- including state and local governments reeling to afford basic workforce benefit packages -- realized significant savings through affiliation with CanaRx, an Ontario-based international pharmacy firm. The firm, which operates in
Illinois, Vermont, Rhode Island and other states, has a solid safety record and earned participants' praise for quality service. Concerns that broader use of mail-order prescription programs like those offered by CanaRx might harm Maine pharmacies aren't strong enough to warrant continuing to block a desperately needed route to savings for patients, government and health-plan administrators.” [Editorial, Bangor Daily News, 6/16/13]
- Portland Press Herald: The Law “Was Passed To Address A 2012 Decision By Then-Attorney General William Schneider That Halted The Popular CanaRx Program, Which Allowed Mainers To Buy Cheaper Prescription Drugs Across The Northern Border.” “Maine’s 2013 law was the first of its kind in the nation. It was passed to address a 2012 decision by then-Attorney General William Schneider that halted the popular CanaRx program, which allowed Mainers to buy cheaper prescription drugs across the northern border.” [Portland Press Herald, 2/24/15]
- Bangor Daily News Editorial: “Concerns That Broader Use Of Mail-Order Prescription Programs Like Those Offered By CanaRx Might Harm Maine Pharmacies Aren’t Strong Enough To Warrant Continuing To Block A Desperately Needed Route To Savings For Patients, Government And Health Plan Administrators.” “The bill restores a lower-cost medication option that for as far back as eight years ago proved beneficial to state workers, Portland city staff and employees of Hardwood Products Co., a private business in Guilford. Before Schneider intervened, employees and employers -- including state and local governments reeling to afford basic workforce benefit packages -- realized significant savings through affiliation with CanaRx, an Ontario-based international pharmacy firm. The firm, which operates in Illinois, Vermont, Rhode Island and other states, has a solid safety record and earned participants' praise for quality service. Concerns that broader use of mail-order prescription programs like those offered by CanaRx might harm Maine pharmacies aren't strong enough to warrant continuing to block a desperately needed route to savings for patients, government and health-plan administrators.” [Editorial, Bangor Daily News, 6/16/13]
- HEADLINE: “Judge Overturns Maine Law Allowing Prescription Drug Imports.” [Bangor Daily News, 2/24/15]
- 2015: Federal Judge Overturned 2013 Maine Law Allowing For Mail-Order Prescription Drug Importation. “A federal judge has overturned Maine’s first-in-the-nation law allowing residents to purchase medication by mail from other countries. U.S. Chief District Judge Nancy Torresen’s ruling Monday comes more than a year after several Maine pharmacy groups filed suit against the state over the 2013 law, arguing it jeopardizes the safety of the nation’s prescription drug supply and opens the door to counterfeit and tainted medications.” [Bangor Daily News, 2/24/15]
In 2018, LePage Refused to Sign a Bipartisan Bill That Required Reporting Of The Top 25 Most-Prescribed Drugs In Maine, The 25 Most Expensive Drugs In Maine, And The 25 Drugs With The Highest Year-To-Year Cost Increases, For Both Generic And Name-
Brand Medications. On May 1, 2018, LD 1406 became law without Governor LePage’s signature after passing both chambers of the Legislature without a roll call vote. “In Maine, lawmakers recently took an important step toward lowering drug prices. A first step in reducing drug prices is to let consumers know the cost of medications they are prescribed. Next, drug makers should explain how they set prices. LD 1406, which became law earlier this month, without Gov. Paul LePage's signature, does both of these things. It requires that the Maine Health Data Organization, starting Dec. 1, issue a report detailing: the 25 most frequently prescribed drugs in Maine; the 25 costliest drugs as determined by the total amount spent on those drugs in the state; and the 25 drugs with the highest year-over-year cost increases as determined by the total amount spent on those drugs. This is for both generic and brand-name medications.” The legislation had bipartisan cosponsors. [Maine State Legislature, LD 1406, 5/1/18; Editorial, Bangor Daily News, 5/15/18]
- The Legislation Required The Health Data Organization To Create A Plan To Collect Data From Drug Manufacturers On Their Drug Pricing Practices In An Effort To Increase Transparency Around The Costs Of Prescription Drugs. “LD 1406, which became law earlier this month, without Gov. Paul LePage's signature, does both of these things. […] It also requires the organization to develop a plan to collect data from manufacturers related to the cost and pricing of prescription drugs in order to provide transparency in and accountability for prescription drug pricing. It is also directed to consult with other state and national agencies and organizations to determine how best to do such data collection. Other states for example, are requiring information about marketing and advertising costs and research and development costs.” [Editorial, Bangor Daily News, 5/15/18]
- The Law Did Not Impose Reporting Requirements On Drug Manufacturers Themselves But Authorized The Maine Health Data Organization To Create A Plan To Collect Data From The Manufacturers. “The Maine Law does not impose any specific reporting requirements on drug manufacturers, but it does authorize the Maine Health Data Organization (MHDO) to create a plan to collect data from manufacturers related to drug costs and pricing with the stated goal of increasing transparency and accountability. The MHDO must create the plan by April 2019, so manufacturers should expect specific reporting requirements to be released within the next year.” [Press Release, Arent Fox, 5/1/18]
- Bangor Daily News Editorial: The Legislation Took The First Steps Toward Lowering Drug Prices In Maine By First, Letting Consumers Know The Cost Of Their Medications And Second, Forcing Drug Makers To Explain How They Set Their Prices. “In Maine, lawmakers recently took an important step toward lowering drug prices. A first step in reducing drug prices is to let consumers know the cost of medications they are prescribed. Next, drug makers should explain how they set prices. LD 1406, which became law earlier this month, without Gov. Paul LePage's signature, does both of these things.” [Editorial, Bangor Daily News, 5/15/18]
- Bangor Daily News Editorial: “Despite Opposition From The Pharmaceutical Industry, The Bill Was Unanimously Passed By Both The House And Senate,
Showing That Lawmakers Can Address Problems When They Work Together.” “Despite opposition from the pharmaceutical industry, the bill was unanimously passed by both the House and Senate, showing that lawmakers can address problems when they work together.” [Editorial, Bangor Daily News, 5/15/18]
In 2018, LePage Refused to Sign Bipartisan Legislation That Required Any Prescription Drug Distributed In Maine Be Available To A Generic Drug Manufacturer That Was Trying To Develop A Cheaper Alternative. On July 4, 2018, LD 1280 became law without Governor LePage’s signature after passing the Senate by a 18-13 vote and the House without a roll call vote. “The bill, L.D. 1280, would amend the Maine Pharmacy Act to require that any drug distributed in Maine be made available for sale to an FDA-approved generic drug manufacturer who is seeking to develop a cheaper alternative.” [Maine State Legislature, LD 1280, 2018; Morning Sentinel, 6/24/17]
- HEADLINE: “Senate OKs Bill Aiming To Cheapen Prescription Drugs.” [Morning Sentinel, 6/24/17]
- HEADLINE: “Lawmakers Endorse Bill To Cut Prescription Drug Cost.” [Portland Press Herald, 6/23/17]
- Morning Sentinel: “The Maine Senate Narrowly Endorsed A Bill Thursday That Would Lower Prescription Drug Prices By Requiring Brand-Name Pharmaceutical Producers To Provide Samples Of Their Drugs To Generic Producers.” “The Maine Senate narrowly endorsed a bill Thursday that would lower prescription drug prices by requiring brand-name pharmaceutical producers to provide samples of their drugs to generic producers.” [Morning Sentinel, 6/24/17]
- National Conference Of State Legislatures: “The New Law ‘Ensures Increased Competition In The Market For Drugs And Biological Products, Which Will Lower The Cost Of Prescription Drugs For Maine Residents And For The State.” “The new law ‘ensures increased competition in the market for drugs and biological products, which will lower the cost of prescription drugs for Maine residents and for the State.’ Amends the Maine Pharmacy Act to require that a drug distributed in this state must be made available for sale in this state to a person seeking to develop an application for the approval of the drug under the Federal Food, Drug, and Cosmetic Act or the licensing of a biological product under the federal Public Health Service Act; establishes disciplinary actions for noncompliance.” [National Conference of State Legislatures, 5/29/19]
- Sens. Troy Jackson (D) And Brian Langley (R): “If Passed, This Bill Would Guarantee Mainers Have Access To Affordable Prescription Drugs By Compelling All Drug Makers To Comply With Federal Laws Designed To Lower The Cost Of Medicine.” “L.D. 1280, AN ACT to Require Drug Manufacturers to Comply with Federal Law, is one of the most important bills the Maine Legislature is considering this session, and we're urging our colleagues to enact it. If passed, this bill would guarantee Mainers have access to affordable prescription drugs by compelling all drug makers to comply with federal laws designed to lower the cost of medicine. This bipartisan measure
received a positive vote of 11-2 from the Joint Standing Committee on Labor, Commerce and Economic Development and has no cost to taxpayers.” [Column – Sens. Troy Jackson (D) and Brian Langley (R), Kennebec Journal, 6/5/17]
- Sens. Troy Jackson (D) And Brian Langley (R): The Legislation “Ensures Competition In The Marketplace By Not Allowing Licensed Manufacturers To Impose Any Restriction On The Sale That Would Block Or Delay Eligible Generic Companies From Engaging In The Testing They Need To Enter The Market.” “L.D. 1280 ensures competition in the marketplace by not allowing licensed manufacturers to impose any restriction on the sale that would block or delay eligible generic companies from engaging in the testing they need to enter the market. The Maine attorney general would be empowered to enforce the law if a company were to avoid selling their samples to a generics company, and compel the brand-name producer to sell its product at a fair market value to the generic company.” [Column – Sens. Troy Jackson (D) and Brian Langley (R), Kennebec Journal, 6/5/17]
- Sens. Troy Jackson (D) And Brian Langley (R): The Legislation “Empowered [The Maine Attorney General] To Enforce The Law If A Company Were To Avoid Selling Their Samples To A Generics Company, And Compel The Brand-Name Producer To Sell Its Product At A Fair Market Value To The Generic Company.” “L.D. 1280 ensures competition in the marketplace by not allowing licensed manufacturers to impose any restriction on the sale that would block or delay eligible generic companies from engaging in the testing they need to enter the market. The Maine attorney general would be empowered to enforce the law if a company were to avoid selling their samples to a generics company, and compel the brand-name producer to sell its product at a fair market value to the generic company.” [Column – Sens. Troy Jackson (D) and Brian Langley (R), Kennebec Journal, 6/5/17]
In 2018, LePage Refused to Sign Bipartisan Legislation That Required Health Insurers To Provide 60 Days Advance Notice To Enrollees About Adverse Changes To Their Prescription Drug Formularies. LD 696 “requires a carrier to provide notice of an adverse change to an enrollee’s prescription drug formulary. At least 60 days’ notice is required, except in instances in which a prescription drug is removed from the formulary because of concerns about safety. The amendment defines ‘adverse change to a formulary’ as a change that removes a drug currently prescribed for that enrollee from the formulary applicable to the enrollee’s health plan or a change that moves the prescribed drug to a tier with a higher cost-sharing requirement if the carrier uses a formulary with tiers.” The House enacted the bill by a 135-0 vote and the Senate without a roll call vote, and the bill became law without Governor LePage’s signature. [Maine State Legislature, LD 696, Roll Call #672, 6/19/18]
In 2015, LePage Refused to Sign Bipartisan Legislation That Required Health Insurers to Allow for Prescriptions to be Dispensed for Less Than a 30-Day Supply if in the Best Interest of the Patient. In May 2015, LePage allowed LD810 to become law without his signature after it passed both chambers without a roll call vote. LD810 “requires that, if a health plan provides coverage for prescription drugs, a carrier must allow prescriptions to be dispensed by a pharmacist for less than a 30-day supply if it is in the best interest of the patient. The law excludes prescriptions for solid oral doses of antibiotics and solid oral doses dispensed in their original container from the requirement.” [Summaries of Bills, LD810, 2015; Maine State Legislature, LD810, 2015]